Next Article in Journal
Ablation of Protein Kinase CK2β in Skeletal Muscle Fibers Interferes with Their Oxidative Capacity
Next Article in Special Issue
Theranostic Value of Multimers: Lessons Learned from Trimerization of Neurotensin Receptor Ligands and Other Targeting Vectors
Previous Article in Journal
Structural Hypervariability of the Two Human Protein Kinase CK2 Catalytic Subunit Paralogs Revealed by Complex Structures with a Flavonol- and a Thieno[2,3-d]pyrimidine-Based Inhibitor
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessReview
Pharmaceuticals 2017, 10(1), 12; doi:10.3390/ph10010012

188Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy

1
Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara 44121, Italy
2
Italy and Legnaro National Laboratories, Italian National Institute for Nuclear Physics (LNL-INFN), Legnaro (PD) 35020, Italy
*
Author to whom correspondence should be addressed.
Academic Editors: Klaus Kopka and Elisabeth Eppard
Received: 7 December 2016 / Revised: 9 January 2017 / Accepted: 16 January 2017 / Published: 19 January 2017
View Full-Text   |   Download PDF [2885 KB, uploaded 19 January 2017]   |  

Abstract

The favorable nuclear properties of rhenium-188 for therapeutic application are described, together with new methods for the preparation of high yield and stable 188Re radiopharmaceuticals characterized by the presence of the nitride rhenium core in their final chemical structure. 188Re is readily available from an 188W/188Re generator system and a parallelism between the general synthetic procedures applied for the preparation of nitride technetium-99m and rhenium-188 theranostics radiopharmaceuticals is reported. Although some differences between the chemical characteristics of the two metallic nitrido fragments are highlighted, it is apparent that the same general procedures developed for the labelling of biologically active molecules with technetium-99m can be applied to rhenium-188 with minor modification. The availability of these chemical strategies, that allow the obtainment, in very high yield and in physiological condition, of 188Re radiopharmaceuticals, gives a new attractive prospective to employ this radionuclide for therapeutic applications. View Full-Text
Keywords: rhenium-188; theranostics; radiopharmaceuticals; radionuclide therapy; peptides; bioconjugates rhenium-188; theranostics; radiopharmaceuticals; radionuclide therapy; peptides; bioconjugates
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Boschi, A.; Martini, P.; Uccelli, L. 188Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy. Pharmaceuticals 2017, 10, 12.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top